|
US3971816A
(en)
*
|
1973-11-26 |
1976-07-27 |
Ceskoslovenska Akademie Ved |
Esters of carboxylic acids formally substituted by sodium or potassium in the alpha-position and the method for their preparation
|
|
US4012523A
(en)
*
|
1974-01-24 |
1977-03-15 |
The Dow Chemical Company |
Hypolipidemic 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-(thio or sulfonyl) alkanoic acids and derivatives
|
|
US4067998A
(en)
*
|
1974-02-11 |
1978-01-10 |
The Dow Chemical Company |
2-((3,5-Di-tert-butylphenyl)thio) alkanoic acids and derivatives
|
|
US4020177A
(en)
*
|
1974-08-30 |
1977-04-26 |
Merck & Co., Inc. |
Substituted phenoxy-tridecanoic acids
|
|
US4024182A
(en)
*
|
1975-08-15 |
1977-05-17 |
Sandoz, Inc. |
Preparation of aryl-butadienoic acids
|
|
US4126637A
(en)
*
|
1977-06-17 |
1978-11-21 |
Warner-Lambert Company |
Process for the production of 2,2-dimethyl-5-(2,5-xylyloxy)valeric acid
|
|
GB2025942A
(en)
*
|
1978-05-31 |
1980-01-30 |
Sori Soc Rech Ind |
Phenoxyalkylcarboxylic acids
|
|
US4285951A
(en)
*
|
1979-09-07 |
1981-08-25 |
Warner-Lambert Company |
2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentyl ester of 3-pyridine carboxylic acid and use as an anti-atherosclerotic agent
|
|
US4477556A
(en)
*
|
1982-08-18 |
1984-10-16 |
E. I. Du Pont De Nemours And Company |
Acidic o-nitroaromatics as photoinhibitors of polymerization in positive working films
|
|
US4665226A
(en)
*
|
1985-12-09 |
1987-05-12 |
Warner-Lambert Company |
Process for preparing 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid
|
|
US4714762A
(en)
*
|
1986-10-31 |
1987-12-22 |
Warner-Lambert Company |
Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
|
|
AU1422388A
(en)
*
|
1987-01-27 |
1988-08-10 |
Warner-Lambert Company |
Lipid regulating compositions
|
|
US4973731A
(en)
*
|
1987-04-23 |
1990-11-27 |
Riker Laboratories, Inc. |
Di-t-butylphenyl alkyl and benzyl ether nitriles
|
|
US4859703A
(en)
*
|
1987-06-15 |
1989-08-22 |
Warner-Lambert Company |
Lipid regulating compositions
|
|
US4968710A
(en)
*
|
1987-11-13 |
1990-11-06 |
Riker Laboratories, Inc. |
Substituted di-t-butylphenols and anti-allergic use thereof
|
|
US5066822A
(en)
*
|
1987-11-13 |
1991-11-19 |
Riker Laboratories, Inc |
Di-t-butylphenols substituted by an alkoxy or benzyloxy group or a benzylthio group
|
|
US5260305A
(en)
*
|
1988-12-12 |
1993-11-09 |
E. R. Squibb & Sons, Inc. |
Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
|
|
US5235097A
(en)
*
|
1990-05-11 |
1993-08-10 |
Egis Gyogyszergyar |
Process for the preparation of 2,2-dimethyl-5-(2,5-dimethyl-phenoxy)-pentanoic acid, intermediates for preparing this compound and process for preparing the intermediates
|
|
HU205891B
(en)
*
|
1990-05-11 |
1992-07-28 |
Gyogyszerkutato Intezet |
Process for producing 2,2-dimethyl-5-/2,5-dimethyl-phenoxy/-pentanoic acid
|
|
US5041640A
(en)
*
|
1990-09-20 |
1991-08-20 |
Warner-Lambert Company |
Process for mono-, di-, trisubstituted acetic acids
|
|
HU212428B
(en)
*
|
1994-05-13 |
1996-06-28 |
Egyt Gyogyszervegyeszeti Gyar |
Process to prepare pharmaceutical compositions containing gemfibrozyl
|
|
US5412112A
(en)
*
|
1994-06-14 |
1995-05-02 |
Industrial Technology Research Institute |
Derivatives and preparation of 2,2-dimethyl-5-substituted phenoxy-pentanoic acids
|
|
US5530145A
(en)
*
|
1994-06-14 |
1996-06-25 |
Syn-Tech Chem & Pharm Co., Ltd. |
Anticholesteremic compounds
|
|
US6262277B1
(en)
*
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
|
DE4446387A1
(de)
*
|
1994-12-23 |
1996-06-27 |
Basf Ag |
Verfahren zur Herstellung fester, freifließender wasserlöslicher Salze von Aryloxi-C¶1¶-C¶4¶-alkancarbonsäuren
|
|
US5648387A
(en)
*
|
1995-03-24 |
1997-07-15 |
Warner-Lambert Company |
Carboxyalkylethers, formulations, and treatment of vascular diseases
|
|
US6713043B2
(en)
*
|
1996-02-29 |
2004-03-30 |
The Trustees Of Columbia University In The City Of New York |
Antimicrobial activity of gemfibrozil
|
|
US5883109A
(en)
*
|
1996-07-24 |
1999-03-16 |
Bristol-Myers Squibb Company |
Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
|
|
AU727895B2
(en)
*
|
1997-01-17 |
2001-01-04 |
Bristol-Myers Squibb Company |
Method for treating atherosclerosis with an MPT inhibitor and cholesterol lowering drugs
|
|
WO1998050028A1
(en)
*
|
1997-05-01 |
1998-11-12 |
Bristol-Myers Squibb Company |
Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels
|
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
|
US6469035B1
(en)
*
|
1997-07-31 |
2002-10-22 |
Eugenio A. Cefali |
Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
|
|
US6083497A
(en)
|
1997-11-05 |
2000-07-04 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
|
|
US6264960B1
(en)
|
1998-11-10 |
2001-07-24 |
Sander J. Robins |
Treatment of vascular events using lipid-modifying compositions
|
|
CN1342091A
(zh)
*
|
1998-12-23 |
2002-03-27 |
G.D.瑟尔有限公司 |
心血管指征的联合用药
|
|
DK1140185T3
(da)
|
1998-12-23 |
2003-09-29 |
Searle Llc |
Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer
|
|
MXPA01006472A
(es)
*
|
1998-12-23 |
2004-03-10 |
Searle Llc |
Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
|
|
PT1140190E
(pt)
|
1998-12-23 |
2003-02-28 |
Searle Llc |
Combinacoes de inibidores do transporte ileal dos acidos biliares e agentes sequestrantes dos acidos biliares usadas para problemas cardiovasculares
|
|
EP1342475A1
(en)
|
1998-12-23 |
2003-09-10 |
G.D. Searle LLC. |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
|
AU2157400A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
|
|
EP1140186B1
(en)
*
|
1998-12-23 |
2003-06-04 |
G.D. Searle LLC. |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
|
DK1140184T3
(da)
*
|
1998-12-23 |
2003-09-29 |
Searle Llc |
Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
|
|
US7279597B1
(en)
|
1999-11-05 |
2007-10-09 |
Emisphere Technologies, Inc. |
Phenyl amine carboxylic acid compounds and compositions for delivering active agents
|
|
US7129274B1
(en)
|
1999-11-05 |
2006-10-31 |
Emisphere Technologies Inc. |
Phenoxy carboxylic acid compounds and compositions for delivering active agents
|
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
|
EP1286984A2
(en)
|
2000-03-10 |
2003-03-05 |
Pharmacia Corporation |
Method for the preparation of tetrahydrobenzothiepines
|
|
WO2001068096A2
(en)
*
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
|
ES2258141T3
(es)
|
2001-04-11 |
2006-08-16 |
Bristol-Myers Squibb Company |
Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
|
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
|
KR20040054729A
(ko)
*
|
2001-10-18 |
2004-06-25 |
브리스톨-마이어스 스큅 컴퍼니 |
인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
|
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
|
US6740663B2
(en)
*
|
2001-11-02 |
2004-05-25 |
G.D. Searle, Llc |
Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
|
|
WO2003043624A1
(en)
*
|
2001-11-16 |
2003-05-30 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
|
AU2003207431A1
(en)
|
2002-01-17 |
2003-09-02 |
Pharmacia Corporation |
Novel alkyl/aryl hydroxy or keto thiepines.
|
|
IL163666A0
(en)
|
2002-02-22 |
2005-12-18 |
New River Pharmaceuticals Inc |
Active agent delivery systems and methods for protecting and administering active agents
|
|
BR0308537A
(pt)
*
|
2002-03-20 |
2005-02-09 |
Metabolex Inc |
Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga
|
|
AU2003225102A1
(en)
*
|
2002-04-23 |
2003-11-10 |
Bristol-Myers Squibb Company |
Modified-release vasopeptidase inhibitor formulation, combinations and method
|
|
US7672397B2
(en)
*
|
2002-05-14 |
2010-03-02 |
Otmar Irscheid |
Method for producing a transmission signal
|
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
|
ATE469645T1
(de)
*
|
2002-10-23 |
2010-06-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
|
US7098235B2
(en)
*
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
|
CN1812983A
(zh)
*
|
2003-05-30 |
2006-08-02 |
兰贝克赛实验室有限公司 |
取代的吡咯衍生物及其作为hmg-co抑制剂的用途
|
|
WO2004108126A1
(en)
*
|
2003-06-06 |
2004-12-16 |
Snowden Pharmaceuticals, Llc |
Fibric acid derivatives for the treatment of irritable bowel syndrome
|
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
|
US7199259B2
(en)
*
|
2003-06-20 |
2007-04-03 |
Metabolex, Inc. |
Resolution of α-(phenoxy)phenylacetic acid derivatives
|
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
US7390504B2
(en)
*
|
2003-11-07 |
2008-06-24 |
Jj Pharma, Inc. |
HDL-boosting combination therapy complexes
|
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
EP1689757B1
(en)
*
|
2003-11-12 |
2014-08-27 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US7317109B2
(en)
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
AU2005247473A1
(en)
*
|
2004-05-25 |
2005-12-08 |
Metabolex, Inc. |
Substituted triazoles as modulators of PPAR and methods of their preparation
|
|
WO2005115384A2
(en)
*
|
2004-05-25 |
2005-12-08 |
Metabolex, Inc. |
Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
|
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
WO2006076598A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
|
US7368458B2
(en)
*
|
2005-01-12 |
2008-05-06 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
|
WO2006076569A2
(en)
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
|
EP1846410B1
(en)
*
|
2005-02-10 |
2009-01-21 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5ht modulators
|
|
EP2527337A1
(en)
|
2005-04-14 |
2012-11-28 |
Bristol-Myers Squibb Company |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
TW200716679A
(en)
*
|
2005-05-26 |
2007-05-01 |
Bristol Myers Squibb Co |
N-terminally modified GLP-1 receptor modulators
|
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
|
TW200726765A
(en)
*
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
|
JP2009502959A
(ja)
*
|
2005-07-28 |
2009-01-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−1h−ピリド[4,3,b]インドール
|
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
|
US7714131B2
(en)
*
|
2005-09-23 |
2010-05-11 |
Metabolex, Inc. |
Process for the stereoselective preparation of (−)-halofenate and derivatives thereof
|
|
US8618115B2
(en)
*
|
2005-10-26 |
2013-12-31 |
Bristol-Myers Squibb Company |
Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
|
|
EP2487154B1
(en)
|
2005-10-31 |
2013-10-16 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
|
SG166829A1
(en)
*
|
2005-11-08 |
2010-12-29 |
Ranbaxy Lab Ltd |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
EP1976873A2
(en)
*
|
2006-01-11 |
2008-10-08 |
Brystol-Myers Squibb Company |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
|
CA2569776A1
(en)
*
|
2006-02-17 |
2007-08-17 |
Kos Life Sciences, Inc. |
Low flush niacin formulation
|
|
WO2008020314A2
(en)
*
|
2006-03-14 |
2008-02-21 |
Ranbaxy Laboratories Limited |
Statin stabilizing dosage formulations
|
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
|
WO2007139589A1
(en)
*
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
|
WO2008010087A2
(en)
*
|
2006-07-14 |
2008-01-24 |
Ranbaxy Laboratories Limited |
Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
|
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
|
CL2007002958A1
(es)
*
|
2006-10-12 |
2008-05-09 |
Epix Delaware Inc |
Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
|
|
EP2089355A2
(en)
|
2006-11-01 |
2009-08-19 |
Brystol-Myers Squibb Company |
Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
|
|
MX2009009126A
(es)
*
|
2007-03-01 |
2009-10-28 |
Concourse Health Sciences Llc |
Isomeros de niacinato de inositol y usos de los mismos.
|
|
TW200901959A
(en)
|
2007-03-09 |
2009-01-16 |
Indigene Pharmaceuticals Inc |
Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
|
|
AR065809A1
(es)
|
2007-03-22 |
2009-07-01 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
|
WO2008130951A1
(en)
|
2007-04-17 |
2008-10-30 |
Bristol-Myers Squibb Company |
Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
|
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
|
JP2010528023A
(ja)
*
|
2007-05-18 |
2010-08-19 |
ブリストル−マイヤーズ スクイブ カンパニー |
Sglt2阻害剤の結晶構造およびその製造方法
|
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
|
CN101808995A
(zh)
*
|
2007-07-27 |
2010-08-18 |
百时美施贵宝公司 |
新颖的葡糖激酶激活剂及其使用方法
|
|
KR100836960B1
(ko)
*
|
2007-09-07 |
2008-06-10 |
주식회사 서울제약 |
새로운 나이아신 제어방출형 제제
|
|
US20100331298A1
(en)
*
|
2007-12-10 |
2010-12-30 |
Cytopathfinder, Inc. |
Carboxamide Compounds and Their Use
|
|
KR20100102646A
(ko)
|
2007-12-11 |
2010-09-24 |
가부시키가이샤 사이토파스파인더 |
카르복스아미드 화합물 및 케모카인 수용체 길항제로서의 이의 용도
|
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
|
SG174504A1
(en)
|
2009-03-27 |
2011-10-28 |
Bristol Myers Squibb Co |
Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
|
|
MX2012005425A
(es)
|
2009-11-13 |
2012-06-14 |
Astrazeneca Uk Ltd |
Formulaciones de metformina de masa reducida.
|
|
ES2689107T3
(es)
|
2009-11-13 |
2018-11-08 |
Astrazeneca Ab |
Formulaciones de tabletas bicapa
|
|
CN104825417A
(zh)
|
2009-11-13 |
2015-08-12 |
阿斯利康(瑞典)有限公司 |
立即释放片剂
|
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
|
WO2011130459A1
(en)
|
2010-04-14 |
2011-10-20 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
|
CN107080846A
(zh)
|
2010-07-09 |
2017-08-22 |
詹姆斯.特林卡.格林 |
用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
|
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
|
IL295438B2
(en)
|
2011-01-05 |
2026-05-01 |
Lexicon Pharmaceuticals Inc |
Compositions containing and methods for using inhibitors of sodium-glucose cotransporters 1 and 2
|
|
EP2892896B1
(en)
|
2012-09-05 |
2016-06-29 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
|
|
EP2892897A1
(en)
|
2012-09-05 |
2015-07-15 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
|
EP2925735B1
(en)
|
2012-11-20 |
2019-03-13 |
Lexicon Pharmaceuticals, Inc. |
Inhibitors of sodium glucose cotransporter 1
|
|
US9132117B2
(en)
|
2013-06-17 |
2015-09-15 |
Kgk Synergize, Inc |
Compositions and methods for glycemic control of subjects with impaired fasting glucose
|
|
US9593113B2
(en)
|
2013-08-22 |
2017-03-14 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
|
WO2016038520A1
(en)
*
|
2014-09-08 |
2016-03-17 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of ticagrelor and its intermediates
|
|
TN2017000344A1
(en)
|
2015-02-06 |
2019-01-16 |
Intercept Pharmaceuticals Inc |
Pharmaceutical compositions for combination therapy
|
|
EP3288584A2
(en)
|
2015-04-30 |
2018-03-07 |
President and Fellows of Harvard College |
Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
|
|
WO2020016335A1
(en)
|
2018-07-19 |
2020-01-23 |
Astrazeneca Ab |
Methods of treating hfpef employing dapagliflozin and compositions comprising the same
|
|
WO2020038464A1
(zh)
*
|
2018-08-23 |
2020-02-27 |
北京厚燊药德科技有限责任公司 |
苯氧酸类化合物及其医药用途
|
|
AU2019346497A1
(en)
|
2018-09-26 |
2021-04-08 |
Lexicon Pharmaceuticals, Inc. |
Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
|
|
EA202193334A1
(ru)
|
2019-05-30 |
2022-03-14 |
Интерсепт Фармасьютикалз, Инк. |
Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени
|
|
CN119431135B
(zh)
*
|
2025-01-10 |
2025-04-08 |
安徽昊帆生物有限公司 |
4-(4-羟甲基-3-甲氧基苯氧基)丁酸的制备方法
|